PTO/SB/21 (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

Total Number of Pages in This Submission

Application Number	10/775,973
Filing Date	February 9, 2004
First Named Inventor	Lawrence W. STANTON
Art Unit	1636
Examiner Name	Not Yet Assigned
Attorney Docket Number	219002031710

ENCLOSURES (Check all that apply)					
Fee Transmittal Form	Drawing(s)	After Allowance Communication to Group			
Fee Attached	Licensing-related Papers	Appeal Communication to Board of Appeals and Interferences			
Amendment/Reply	Petition	Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)			
After Final	Petition to Convert to a Provisional Application	Proprietary Information			
Affidavits/declaration(s)	Power of Attorney, Revocation Change of Correspondence Address	Status Letter			
Extension of Time Request	Terminal Disclaimer	X Other Enclosure(s) (please identify below):			
Express Abandonment Request	Request for Refund	Form PTO-1449, 6 pages Return Postcard			
Information Disclosure Statement, 3 pages	CD, Number of CD(s)				
Certified Copy of Priority Document(s)					
Response to Missing Parts/ Incomplete Application	Remarks				
Response to Missing Parts under 37 CFR 1.52 or 1.53	CUSTOMER NO. 2522	5			
CICNATI	UDE OF ARRIVOANT ATTORNEY OF	ACCUT			
SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT					
Firm MORRISON & FOERSTER LLP					
Individual name James J. Mullen, III - 44,957					
Signature					
Date June 29, 2004					
I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail, in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA*22313-1450, on the date shown below.					

Dated: June 29, 2004



CERTIFICATE OF MAILING BY "FIRST CLASS"

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450, on June 29, 2004.

Rhea Amid

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the application of:

Lawrence W. STANTON et al.

Serial No.:

10/775,973

Filing Date:

February 9, 2004

For:

SECRETED FACTORS

Examiner: Not Yet Assigned

Group Art Unit: 1636

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.97 & 1.98

Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450

Dear Sir:

Pursuant to 37 C.F.R. § 1.97 and § 1.98, Applicants submit for consideration in the above-identified application the documents listed on the attached Form PTO-1449. Copies of the documents were previously submitted in an Information Disclosure Statement and/or Office Action, directed to the related application Serial Number 09/665,976 filed 20 September 2000 and, accordingly, copies are not included herewith. This protocol conforms with 37 C.F.R. §1.98(d) and M.P.E.P. 609(A)(2). The Examiner is requested to make these documents of record in the application.

	This In	formation Disclosure Statement is submitted:
	With	the application; accordingly, no fee or separate requirements are required.
\boxtimes	Withi	n three months of the application filing date or before mailing of a first Office
	Actio	n on the merits; accordingly, no fee or separate requirements are required.
	After	receipt of a first Office Action on the merits but before mailing of a final Office
	Actio	n or Notice of Allowance.
		A fee is required. A check in the amount of * is enclosed.
		A fee is required. Accordingly, a Fee Transmittal form (PTO/SB/17) is attached
		to this submission in duplicate.
		A Certification under 37 C.F.R. § 1.97(e) is provided below; accordingly; no fee
		is believed to be due.
	After	mailing of a final Office Action or Notice of Allowance, but before payment of the
	issue	fee.
		A Certification under 37 C.F.R. § 1.97(e) is provided below and a check in the
		amount of * is enclosed.
		A Certification under 37 C.F.R. § 1.97(e) is provided below and a Fee Transmittal
		form (PTO/SB/17 is attached to this submission in duplicate.

Applicants would appreciate the Examiner initialing and returning the Form PTO-1449, indicating that the information has been considered and made of record herein.

The information contained in this Information Disclosure Statement under 37 C.F.R. § 1.97 is not to be construed as a representation that: (i) a complete search has been made; (ii) additional information material to the examination of this application does not exist; (iii) the information, protocols, results and the like reported by third parties are accurate or enabling; or (iv) the above information constitutes prior art to the subject invention.

In the unlikely event that the transmittal letter is separated from this document and the Patent Office determines that an extension and/or other relief is required, applicant petitions for any required relief including extensions of time and authorizes the Commissioner to charge the

cost of such petitions and/or other fees due in connection with the filing of this document to

<u>Deposit Account No. 03-1952</u> referencing <u>219002031710</u>. However, the Commissioner is not authorized to charge the cost of the issue fee to the Deposit Account.

Dated: June <u>29</u>, 2004

Respectfully submitted,

By:

ames J Mullen, III, Ph.D.

Reg. No. 44,957

Morrison & Foerster LLP

3811 Valley Centre Drive, Suite 500 San Diego, California 92130-2332

Telephone: (858) 720-5112 Facsimile: (858) 720-5125 JUL 0 2 2004 %

Form PTO-1449

INFORMATION IN AN APPLICATION

(Use several sheets if necessary)

	Sheet 1 01 0				
Docket Number 219002031710	Application Number 10/775,973				
Applicant	•				
Lawrence	: W. STANTON et al.				
Filing Date February 9, 2004 Group Art Unit 1636					
Mailing Date June 29 2004					

U.S. PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Name	Class	Subclass	Filing Date If Appropriate
	1.	06/1965	3,187,748	Mitchell et al.	128	200.23	
	2.	06/1974	3,814,297	Warren	222	402.13	
-	3.	07/1974	3,826,413	Warren	222	402.13	
	4.	07/1985	4,527,769	Stogner et al.	251	14	
	5.	06/1986	4,592,348	Water, IV, et al.	128	200.23	
	6.	03/1987	4,648,393	Landis et al.	128	200.23	
	7.	07/1987	4,677,975	Edgar et al.	128	200.14	
	8.	07/1987	4,683,195	Mullis et al.	435	6	·
	9.	12/1988	4,790,305	Zoltan et al.	128	200.23	
	10.	02/1989	4,803,978	Johnson, IV, et al.	128	200.23	
-	11.	03/1989	4,816,567	Cabality et al.	530	387.3	_
	12.	10/1989	4,873,191	Wagner et al.	800	25	
	13.	01/1990	4,896,832	Howlett	239	322	
	14.	05/1990	4,926,852	Zoltan et al.	128	200.23	
	15.	07/1990	4,943,529	Van den Berg et al.	435	6	
-	16.	02/1991	4,992,901	Keel et al.	360	110	
	17.	06/1995	5,428,130	Capon et al.	530	350	
•	18.	08/1996	5,545,806	Lonberg et al.	800	6	
	19.	08/1996	5,545,807	Surani et al.	800	2	
	20.	02/1998	5,719,125	Suzuki et al.	514	12	
	21.	10/1996	5,569,825	Lonberg et al.	435	172.3	
	22.	04/1997	5,625,126	Lonberg et al.	800	2	
	23.	08/1997	5,661,016	Lonberg et al.	435	172.3	
	24.	09/1997	5,665,600	Hangenson et al.	435	320.1	
	25.	02/1998	5,716,785	Van Gelder et al.	435	6	
	26.	04/1998	5,744,305	Fodor et al.	435	6	
	27.	09/1998	5,800,992	Fodor et al.	435	6	

EXAMINER:

DATE CONSIDERED:

Form PTO-1449 INFORMATION DISCLOSURE CITATION IN AN APPLICATION

(Use several sheets if necessary)

Docket Number 219002031710 Application Number 10/775,973 Applicant Lawrence W. STANTON et al.

Filing Date February 9, 2004 Group Art Unit 1636

Mailing Date June 29, 2004

28.	09/1998	5,807,522	Brown et al.	422	50	

FOREIGN PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Country	Class	Subclass	Translation YES NO
_	29.	09/1991	EP 0 183 070	Europe			
_	30.	08/1994	EP 0 373 203	Europe			
	31.	01/1988	WO 88/00239	PCT			
	32.	03/1988	WO 88/01648	PCT			
·	33.	12/1988	WO 88/10118	PCT			
	34.	04/1989	WO 89/02922	PCT			
	35.	11/1989	WO 89/10977	PCT			
	36.	06/1991	WO 91/08216	PCT			
	37.	08/1999	WO 99/40189A	PCT			

OTHER DOCUMENTS

(including author, title, Date, Pertinent Pages,

		(including dathor, fine, bute, retinent rage
Examiner . Initials	Ref. No.	Title
	38.	Abravaya et al., Nuc Acids Res 23(4):675-682 (1995).
	39.	Accession No. AA891470 (June 1998).
	40.	Adelman et al., DNA 2(3):183-193 (1983).
	41.	Anthony, C., "The Biochemistry of Methylotrophs" Dept. of Biochem., Univ of Southampton, Eng., Ch. 10:269-295, Academic Press (1982).
	42.	Arola et al., J Med Vir 47:251-259 (1995).
•	43.	Askari and McDonnell, The New Eng J of Med 334:316-318 (1996).
	44.	Ausubel et al., "Current Protocols in Molecular Biology" eds. (1987).
	45.	Beach et al., Nature 290:140-142 (1981).
	46.	Beaucage et al., Tetrah Letts 22(20):1859-1862 (1981).
	47.	Boerner et al., J of Immunol 147(1):86-95 (1991).

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

PTO/SB/ 08 (2-92) sd- 185976

Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

JUL 0 2 2004 %

Form PTO-1449

INFORMATION DISCLOSURE CITATION IN AN APPLICATION

(Use several sheets if necessary)

Sheet 3 of 6

Docket Number 219002031710 Application Number 10/775,973

Applicant

Lawrence W. STANTON et al.

Filing Date February 9, 2004 Group Art Unit 1636

Mailing Date June 29, 2004

	(Use several sneets if necessary)		rining Date reducity 9, 2004	Group Art Unit 1636		
			Mailing Date June <u>29</u> , 2004			
	48.	Bolivar et al., Gene 2:95-113 (1977).				
	49.	Botstein and Shortle, Science 220(4719):1193-1201 (1985).				
	50.	Brake et al., PNAS USA 81:4646 (19	Brake et al., <i>PNAS USA</i> 81:4646 (1984).			
-	51.	Carter et al., Nucl Acids Res 13:4331	(1986).			
	52.	Chevray et al., PNAS USA 89:5789-	5793 (1992).			
	53.	Chien et al., PNAS USA 88:9578-95	82 (1991).			
	54.	Chien et al., The FASEB J 5:3037-30	046 (1991).			
	55.	Chomzynski et al., Anaytical Bioche	em 162:156-159 (1987).			
	56.	Chow et al., Lab Invest 64(1):55-64	(1991).			
	57.	Cohen et al., Nature 366:698-701 (1	993).			
	58.	Cowley Jr. et al., Kidney Internatl. 4	3:522-534 (1993).			
	59. Creighton, T. E., "Proteins – Structure and Molecular Properties," 2 nd Ed., W.H. Freeman an New York (1993) pp. 34-49.			2 nd Ed., W.H. Freeman and Co.,		
	60.	DATABASE EMBL 'online! Hinston UK (1998-04-06) Lee et al; XP002159902 EMBL Sequence Accession No. AA891420, abstract.				
•	61.	DATABASE EMBL 'online! Hinston UK (1998-10-08) "EST213421 Normalized rat heart, Bent Soares Rattus sp. CDNA clone RHEBX65 3' end, mRNA sequence."				
	62.	Dunmon et al., J Mol Cell Cardiol 2	2:901-910 (1990).	· · · · · · · · · · · · · · · · · · ·		
	64.	Dzau et al., TIBTECH 11:205-210 (1993).	**************************************		
	65.	Fields and Song, Nature 340:245-24	6 (1989).			
	66.	Fiers et al., Nature 273:113-120 (19	78).			
·	67.	Fishwild et al., Nature Biotech 14:84	45-851 (1996).			
	68.	French, A. W., Science 256:808-813	3 (1992).	, <u>" " " " " " " " " " " " " " " " " " "</u>		
	69.	Freshney, "Animal Cell Culture" ed	. IRL Press (1987).			
	70.	Gait, M.J. (Ed.) "Oligonucleotide Sy	nthesis, A Practical Approach	"IRL Press, England (1984).		
	71.	Goeddel et al., Nature 281:544-548	(1978).			
	72.	Gordon, Jon W., Internatl Rev of Ci.	tology 115-171-229.			
	73.	Graham et al., J. Gen Virol 36:59 (1	977).			
	74.	Gu et al., Science 265:103-1006 (19	···	-		
_	75.	Hathaway et al., J of Biolog Chem 2	256(15):8183-8189 (1981).			
	76.	Heller et al., PNAS USA 94:2150-21				
EXCAR	ADIED:		DATE CONSIDERED:	The second secon		

EXAMINER:

DATE CONSIDERED:

JUL 0 2 2004 3

Form PTO-1449 INFORMATION DISCUSSION OF THE PROPERTY OF THE PR

(Use several sheets if necessary)

Docket Number 219002031710 Application Number 10/775,973

Applicant

Lawrence W. STANTON et al.

Filing Date February 9, 2004 Group Art Unit 1636

Mailing Date June 29, 2004

	(Use s	everal sheets if necessary)	Filing Date February 9, 2004	Group Art Unit 1636			
			Mailing Date June <u>29</u> , 2004				
	77.		innen et al., PNAS USA 75(4):1929-1933 (1978).				
	78.	Hitzeman et al., J Biol Chem 225(24	<u></u>				
	79.	Hochuli et al., J of Chromotog 411:1					
	80.	Hohenadl et al., Mol and Cell Probe	Hohenadl et al., Mol and Cell Probes 5:11-20 (1991).				
	81.	Hoogenboom and Winter. J Mol Bio	<i>l</i> 227:381-388 (1992).				
	82.	Hougthen et al., <i>Nature</i> 354:84-86 (1	1991).				
	83.	Hubank et al., Nuc Acids Res 22(25)	:5640-5648 (1994).				
	84.	Ito et al., Nucl Acids Res 10(5):1755	-1769 (1982).				
	85.	Jacobs et al., Gene 198:289-296 (199	97).				
	86.	Jiang et al., Oncogene 10:1855-1864	(1995).				
	87.	Jones et al., Nature 321:522-525 (19	86).				
	88.	Karmali et al., Br J Cancer 48:689-9	06 (1983).				
	89.	Klein et al., PNAS USA 93:7108-711	3 (1996).				
	90.	Knoll et al., Biochem & Biophys Res	: Comm 221:402-407 (1996)).			
	91.	Krimpenfort et al., Biotech. 9:844-84	47 (1991).				
	92.	Kunkel et al., Methods Enzymol 154	:367-82 (1987).				
	93.	Lakso et al., PNAS USA 89:6232-62	36 (1992).				
	94.	Lam et al., Nature 354:82-84 (1991)					
	95.	Landegren et al., Science 241:1077-	1080 (1988).				
\	96.	Lavitrano et al., Cell 57:717-723 (19	989).				
	97.	Liang et al., Science 257:967-971 (1	992).				
	98.	Lo, Cecilia W., Mol Cell Biol 3:1803	3-14 (1983).				
	99.	Lockhart et al., Biotech US 14(14):1	675-1680 (1996).				
	100.	Lonberg and Huszar, Intern Rev Imm	nunol 13:65-93 (1995).				
	101.	Lonberg et al., <i>Nature</i> 368:856-859	(1994).				
	102.	Mahadeva et al., J Mol Biol 284:139	1-1398 (1998).	ar a			
	103.			ns and Structure" 4 th ed., John Wiley			
	104.	Marks et al., J Mol Biol 222:581-59	7 (1991).				
	105.	Mason et al., Circulation 79:971:979	9 (1989).	,			

EXAMINER:

DATE CONSIDERED:

JUL 0 2 2004 34

)mi P1O-1449	12	END.	
INFORMATI	ONDIECT	OSURE C	ITATION
IN	AN APPL	ICATION	•

(Use several sheets if necessary)

	Sheet 5 of 6
Docket Number 219002031710	Application Number 10/775,973
Applicant	
Lawrence	e W. STANTON et al.
Filing Date February 9, 2004	Group Art Unit 1636
Mailing Date June 29, 2004	

		Mailing Date June <u>//</u> , 2004			
	106.	Matteucci and Caruthers, J Amer Chem Soc 103:3185-3191 (1981).			
	100.				
	108.	McClelland and Welsh, Calif Instit of Bio Res, La Jolla, CA, PCR Methods and Applications 4:566-581 (1994).			
	109.	McManus et al., Clin Immunol and Immunopath 68(2):159-169 (1993).			
	110.	Miller and Calos (Eds.) Curr Comm In Mol Biol (1987).			
	• 111.	. Morrison, Sherie L., <i>Nature</i> 368:812-813 (1984).			
	112.	. Mullis et al., "PCR: The Polymerase Chain Reaction" ed. Birkhauser (1994).			
	113.	Munson and Rodbard, Anal Biochem 107:220-239 (1980).			
	114.	Nakawaza et al., PNAS USA 91:360-364 (1994).			
-	115.	. Neuberger, M. Nat Biotech 13:826 (1996).			
	116.	O'Reilley et al., "Baculovirus Expression Vectors: A Laboratory Manual," Oxford University Press (1994)			
	117.	Pfeiffer et al., Circ Res 57(1):84-95 (1985).			
-	118.	Proudfoot et al., J Biol Chem 271:2599-2603 (1996).			
	119.	Ralph et al., PNAS USA 90:10710-10714 (1993).			
	120.	Rattan et al., Ann NY Acad Sci 663:48-62 (1992).			
	121.	Redekop and Naus, J Neurosurg 82:83-90 (1997).			
	122.	Reinsfeld and Sell (Eds) "Monoclonal Antibodies and Cancer Therapy," Proceedings of the Roche-UCLA Symposium held in Park City, UT 1/16-2/2/85, Alan R. Liss Inc. NY (1985).			
	123.	Riechmann et al., Nature 333:323-327 (1988).			
	124.	Sagerstrom et al., Annu Rev Biochem 66:751-783 (1997).			
	125.	Saleh et al., Cancer Res 56:393-401 ((1996).			
	126.	Sambrook et al., "Molecular Cloning: A Laboratory Manual," 2 nd Ed., Sec 1.82, 16.32-16.37.			
	127.	Schena et al., PNAS USA 93:10614-10619 (1996).			
128. Schena et al., Science 270:467-470 (1995). 129. Schunkert et al., J Clin Invest 86:1913-1920 (1990).		Schena et al., Science 270:467-470 (1995).			
		Schunkert et al., J Clin Invest 86:1913-1920 (1990).			
	130.	Seifter et al., Meth Enzymol 182:626-646 (1990).			
	131.	Singleton and Sainsbury, "Dictionary of Microbiology and Molecular Biology, 2 nd ed., J. Wiley & Sons, (New York, NY 1994).			
	132.	Sloane, B.F., Nat Biotech 14:826-7 (1996).			

EXAMINER:

DATE CONSIDERED:

INFORMATION DISCLOSURE CITAT	ION
IN AN APPLICATION	

	Direct 0 01 0	
Docket Number 219002031710	9002031710 Application Number 10/775,973	
Applicant		
Lawrence	W. STANTON et al.	
Filing Date February 9, 2004	Group Art Unit 1636	

	(Use several sheets if necessary)		Filing Date February 9, 2004	Group Art Unit 1636		
			Mailing Date June <u>29</u> , 2004			
	133.	Small et al., Mol Cell Biol 5:64	2-48 (1985).			
	134.	Songyang et al., Cell 72:767-78	3 (1993).			
	135.	Sreekrishna et al., J Basic Micr	robiol 28:165-278 (1988).			
	136.	Studier et al., Methods Enzymo	l 185:60-98 (1990).			
	137.	Tashiro et al., Science 361:600-603 (1993).				
	138.	Thompson et al., Cell 56:313-21 (1989).				
	139.	id Proteins," Methods in Ezymology				
	140.	Tonkinson and Stein, Cancer Invest 14(1):54-65 (1996).				
	141.	Velculescu et al., Science 270:484-487 (1995).				
••	142.	Verhoeven et al., Science 239:1534-1536 (1988).				
	143.	Wagner, R.W., Nature 372:333-335 (1992).				
	144.	Wan et al., Nature Biotech 14:1685-1691 (1996).				
	145.	Warzocha and Wotowiec, Leuk Lymphoma 24:267-281 (1997).				
	146.	Watson et al., Dev Neurosci 15:77-86 (1993).				
	147.	Weir and Blackwell, "Handbook of Experimental Immunology," 4 th ed.				
	148.	Wells et al., Gene 34:315-323 (1985).				
	149.					
	150.	Wetmur, Crit Rev in Biochem and Mol Biol 26(34):227-259 (1991).				
	151.	Yang et al., Circ Res 704-712 (1999).				
	152.	Yokoyama-Kobayashi et al., G	ene 163:193-196 (1995).			
153. Zamecnik et al., PNAS USA 83:4143-4146 (1996).						
	154.	Zapata et al., Protein Eng 8(10):1057-1062 (1995).			
	155. Zhang et al., Science 2		-1272 (1997).			
	156.					
	157.					
	158.	Zoller et al., Nucl Acids Res 10(20):6487-6500.				

EXAMINER:

DATE CONSIDERED: